Novartis aims to cure cancer with CART
This article was originally published in Scrip
Executive Summary
"Our dream is to cure cancer," Alessandro Riva, Novartis's global head of oncology development and medical affairs told an audience of journalists at a recent media event in Switzerland. The company believes that its chimeric antigen receptor T-cell (CART) therapies could be a way to fulfil that dream.